CURES WITHIN REACH RESEARCHER SPOTLIGHT:

A LEADER IN NEUROPSYCHIATRIC TREATMENTS

In 2014, Cures Within Reach collaborated with the Alzheimer's Drug Discovery Foundation and others to fund **Dr. Krista Lanctôt** at **Sunnybrook Health Sciences Centre** and this now-completed randomized, placebo-controlled clinical trial testing nabilone, a cannabinoid used to treat nausea and vomiting caused by cancer chemotherapy, to treat agitation in Alzheimer's disease. She is now leading the larger, confirmatory Phase III trial.

Dr. Lanctôt is a distinguished figure in clinical pharmacology, with over 400 published manuscripts. She holds the Bernick Chair in Geriatric Psychopharmacology at Sunnybrook Health Sciences Centre and the University of Toronto. Her research is concentrated on neurocognitive disorders, with an emphasis on Alzheimer's disease and vascular cognitive impairment. She serves as Sunnybrook's Director of Neuropsychopharmacology Research Program and Research Director of Psychiatry, where her pioneering research is significantly contributing to the understanding and treating neurological conditions. In addition, she is a Professor of Psychiatry and of Pharmacology and Toxicology, and Vice Chair, Basic and Clinical Sciences in the Department of Psychiatry at the University of Toronto.

She was drawn to her focus in neuropsychiatric symptoms of dementia-related diseases (mood and behavior symptoms such as apathy and agitation), due to their significant impact yet lack of treatment options. Her goal: to find treatment options that reduce the impact of these neuropsychiatric symptoms.



Dr. Krista Lanctôt



PROFILE

Dr. Krista Lanctôt earned her PhD from the University of Toronto and is currently the Director of the Neuropsychopharmacology Research Program at the Sunnybrook Health Science Centre in Toronto.

CWR FUNDING

- This \$320,000 clinical study (including \$30,000 from CWR) tested nabilone for agitation in Alzheimer's disease.
- Dr. Lanctôt and this trial represent one of Cures
 Within Reach's communities:
 - Neurology



Cures Within Reach leverages the speed, safety and cost-effectiveness by testing approved therapies for new indications, driving more treatments to more patients more quickly.